ATE343634T1 - Gaba b-rezeptor-subtypen gaba b-r1c und gaba b-r2 und deren heterodimere - Google Patents

Gaba b-rezeptor-subtypen gaba b-r1c und gaba b-r2 und deren heterodimere

Info

Publication number
ATE343634T1
ATE343634T1 AT99943118T AT99943118T ATE343634T1 AT E343634 T1 ATE343634 T1 AT E343634T1 AT 99943118 T AT99943118 T AT 99943118T AT 99943118 T AT99943118 T AT 99943118T AT E343634 T1 ATE343634 T1 AT E343634T1
Authority
AT
Austria
Prior art keywords
gaba
gabab
receptor
novel
heterodimers
Prior art date
Application number
AT99943118T
Other languages
English (en)
Inventor
Ashley Antony Barnes
Alan Wise
Fiona Hamilton Marshall
Neil James Fraser
Julia Helen Margaret White
Steven Michael Foord
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9819420.2A external-priority patent/GB9819420D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE343634T1 publication Critical patent/ATE343634T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99943118T 1998-09-07 1999-09-03 Gaba b-rezeptor-subtypen gaba b-r1c und gaba b-r2 und deren heterodimere ATE343634T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9819420.2A GB9819420D0 (en) 1998-09-07 1998-09-07 Novel receptor
US10367098P 1998-10-09 1998-10-09

Publications (1)

Publication Number Publication Date
ATE343634T1 true ATE343634T1 (de) 2006-11-15

Family

ID=26314336

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99943118T ATE343634T1 (de) 1998-09-07 1999-09-03 Gaba b-rezeptor-subtypen gaba b-r1c und gaba b-r2 und deren heterodimere

Country Status (7)

Country Link
EP (1) EP1109901B1 (de)
JP (1) JP2002524074A (de)
AT (1) ATE343634T1 (de)
AU (1) AU5639799A (de)
DE (1) DE69933776T2 (de)
ES (1) ES2275351T3 (de)
WO (1) WO2000014222A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1044265A4 (de) * 1998-08-27 2002-10-29 Synaptic Pharma Corp Dna, die für ein gaba br2 polypeptid kodiert und deren verwendungen
JP4581277B2 (ja) * 2000-03-28 2010-11-17 味の素株式会社 非意図的行動抑制用医薬組成物、および、ランニングニューロン抑制物質の該医薬組成物製造のための使用
EP1297341A2 (de) * 2000-06-19 2003-04-02 Merck Frosst Canada Inc. Verfahren zur identifizierung von gabab-rezeptor-subtypspezifischen agonisten
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US7175983B2 (en) 2001-11-02 2007-02-13 Abmaxis, Inc. Adapter-directed display systems
AU2004272302A1 (en) * 2003-09-12 2005-03-24 Janssen Pharmaceutica N.V. Chimeric GABAb receptor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69732631T2 (de) * 1996-05-30 2005-12-29 Novartis Ag Metabotropische gaba(b) rezeptoren, rezeptoren-spezifische liganden und deren anwendungen
AU1101099A (en) * 1997-10-17 1999-05-10 Synaptic Pharmaceutical Corporation Dna encoding a gababr2 polypeptide and uses thereof
WO1999021890A1 (en) * 1997-10-27 1999-05-06 Astrazeneca Ab New nucleotide sequences
WO1999040114A1 (en) * 1998-02-05 1999-08-12 Merck & Co., Inc. Novel gabab receptor dna sequences
EP0937777A3 (de) * 1998-02-20 1999-11-24 Smithkline Beecham Plc GABA Rezeporen und deren Anwendungen
WO1999042603A1 (en) * 1998-02-20 1999-08-26 Smithkline Beecham Corporation GABAB-R2a, A 7TM RECEPTOR
WO1999051636A2 (en) * 1998-04-03 1999-10-14 Nps Pharmaceuticals, Inc. Gaba b receptor
IL138747A0 (en) * 1998-04-03 2001-10-31 Nps Pharma Inc G-protein fusion receptors and chimeric gabab receptors
AUPP438498A0 (en) * 1998-06-29 1998-07-23 Garvan Institute Of Medical Research Novel Gaba-B receptor

Also Published As

Publication number Publication date
EP1109901B1 (de) 2006-10-25
WO2000014222A2 (en) 2000-03-16
JP2002524074A (ja) 2002-08-06
AU5639799A (en) 2000-03-27
DE69933776D1 (de) 2006-12-07
DE69933776T2 (de) 2008-01-03
WO2000014222A3 (en) 2000-07-06
ES2275351T3 (es) 2007-06-01
EP1109901A2 (de) 2001-06-27

Similar Documents

Publication Publication Date Title
ATE377606T1 (de) Zyklische antagonisten der c5a rezeptoren sowie der g-protein gekoppelten rezeptoren
ATE474852T1 (de) Nukleinsäuren, die für einen an ein g-protein gekoppelten, an der sensorischen transduktion beteiligten rezeptor kodieren
ATE466030T1 (de) Neues screening-verfahren
DE60329030D1 (de) Melanocortin-rezeptormodulatoren
IS5543A (is) Nýr G próteintengdur viðtaki
YU34898A (sh) Antagonisti ccr-3 receptora
EA200500536A1 (ru) Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
EA200701192A1 (ru) Антагонисты toll-подобного рецептора 3, способы их получения и применение
CY1107339T1 (el) Mu-1, μελος της οικογενειας υποδοχεα κυτοκινης
DK1405083T3 (da) Naturlig ligand af GPCR ChemR23 og anvendelser deraf
MA28015A1 (fr) Composes chimiques
PE20010516A1 (es) Peptidos ciclicos con afinidad mejorada por los receptores de somatostatina
ATE343634T1 (de) Gaba b-rezeptor-subtypen gaba b-r1c und gaba b-r2 und deren heterodimere
BR9814161A (pt) Método de sìntese de pirrolamidas
ATE511644T1 (de) Neues screening-verfahren
ATE494550T1 (de) Neues screening-verfahren
WO2003082320A1 (fr) Nouveau procede de criblage
EP1559721A4 (de) Neue fprl1-liganden und deren verwendung
WO2004083394A3 (en) Human g protein-coupled receptors and modulators thereof for the treatment of inflammatory disorders
SE9804274D0 (sv) Novel receptor
BRPI0412255A (pt) tratamento da disfunção sexual masculina
EA200001017A1 (ru) КОНВЕРГЕНТНЫЙ СИНТЕЗ α-АРИЛ-β-КЕТОНИТРИЛОВ
DE60036712D1 (de) G-Protein gekoppelter REZEPTOR
ATE445159T1 (de) Neues screening-verfahren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties